Because diseases directly associated with a genetic aberration are amenable to oligonucleotide-based intervention, antisense systems for BCR-ABL1 suppression represent a promising treatment option for CML. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.